Cardiologist Matt Cavender of Brigham and Women’s Hospital in Boston says that in a study of about 2,000 patients at least 75 years of age, those who received cangrelor prior to percutaneous coronary intervention fared better than those who received clopidogrel, mirroring results in younger patients.

Robert Andtbacka of the University of Utah discusses plans for a phase 3 trial involving PV-10 in patients with stage 3b and 3c melanoma who have failed or were not candidates for immunotherapy and patients who are BRAF-negative: Patients who currently don’t have good treatment options.

11th International Congress of the Society for Melanoma Research, November 2014